| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8436185 | JANSSEN BIOTECH | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
Apr, 2029
(4 years from now) | |
| US8071623 | JANSSEN BIOTECH | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
Mar, 2031
(6 years from now) | |
| US11091459 | JANSSEN BIOTECH | Niraparib compositions |
Mar, 2038
(13 years from now) | |
| US11673877 | JANSSEN BIOTECH | Niraparib compositions |
Mar, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071579 | JANSSEN BIOTECH | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(3 years from now) | |
| US8143241 | JANSSEN BIOTECH | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(3 years from now) | |
| US8859562 | JANSSEN BIOTECH | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(7 years from now) | |
| US11207311 | JANSSEN BIOTECH | Method of treating prostate cancer |
Jul, 2037
(13 years from now) | |
Akeega is owned by Janssen Biotech.
Akeega contains Abiraterone Acetate; Niraparib Tosylate.
Akeega has a total of 8 drug patents out of which 0 drug patents have expired.
Akeega was authorised for market use on 11 August, 2023.
Akeega is available in tablet;oral dosage forms.
Akeega can be used as a method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation.
The generics of Akeega are possible to be released after 27 March, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 11, 2026 |
Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 11 August, 2023
Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation
Dosage: TABLET;ORAL
AKEEGA family patents
